A key finding is that patients with HER2+ and triple-negative subtypes who have achieved complete tumor disappearance in the breast have a higher chance of achieving complete tumor disappearance in the axilla, which allows for less aggressive axillary surgery. This evidence concerns the gene ERBB2 and neoplasm.